Revealing the molecular signals involved in B and T cell activation is critical to the future discovery of therapeutics that can augment cell-mediated immune responses to disease.1,2,3 CD150 is a type I transmembrane glycoprotein that is involved in signal transduction of antigen specific responses in B and T cells. It is expressed by activated B cells isolated from tonsils and peripheral blood, B cells in germinal centers and mantle zone of lymph nodes, immature thymocytes, and CD45RO+CD45RA- subpopulation of T cells.4,5 This antibody has been used to detect CD150 in neoplastic cells from diffuse large B-cell lymphoma, Hodgkin’s disease, hairy cell leukemia, and some tumors of ectodermal origin.6
1. Mikhalap, S.V., Shlapatska, L.M., Yurchenko, O.V., et al. The adaptor protein SH2D1A regulates signaling through CD150 (SLAM) in B cells. Blood 104(13) 4063-4070 (2004).
2. Mikhalap, S.V., Shlapatska, L.M., Berdova, A.G., et al. CDw150 associates with src-homology 2-containing inositol phosphatase and modulates CD95-mediated apoptosis. J Immunol 162 5719-5727 (1999).
3. Shlapatska, L.M., Mikhalap, S.V., Berdova, A.G., et al. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J Immunol 166 5480-5487 (2001).
4. Cocks, B.G., Chang, C.J., Carballido, J.M., et al. A novel receptor involved in T-cell activation. Nature 376 260-263 (1995).
5. Sidorenko, S.P., Clark, E.A. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 151 4614-4624 (1993).
6. Pinchouk, V.G., Sidorenko, S.P., Gluzman, D.F., et al. Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens. Anticancer Res 8 1377-1380 (1988).